Pharmacia & Upjohn's Rogaine Rx-to-OTC switch recommended for approval Nov. 17.
This article was originally published in The Tan Sheet
Executive Summary
ROGAINE Rx-TO-OTC SWITCH RECOMMENDED FOR APPROVAL by FDA's Nonprescription Drugs and the Dermatologic and Ophthalmic Drug Advisory Committees on Nov. 17. The joint committee voted 12 to 4 to recommend to FDA that Pharmacia & Upjohn's Rogaine (minoxidil 2%) be allowed to be sold as an over-the-counter hair regrowth treatment for men and women with androgenetic alopecia (hereditary hair loss).